Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Mar;102(3):288-290.
doi: 10.1111/cen.15193. Epub 2024 Dec 29.

Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?

David S McLaren  1   2 , Nikolaos Kyriakakis  1 , Khyatisha Seejore  1 , Julie Lynch  1 , Robert D Murray  1   2
Affiliations
Editorial

Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?

David S McLaren et al. Clin Endocrinol (Oxf). 2025 Mar.

Abstract

With the current therapeutic modalities available to endocrinologists, control of GH and IGF-I is now possible in almost all patients with acromegaly with multi-modality therapy. Despite biochemical control of GH and IGF-I, patients with acromegaly continue to experience impaired quality of life. Although there are likely multiple factors contributing to this dissatisfaction with current medical therapies, in particular the widely utilised injectable long-acting somatostatin receptor ligands (iSRL), is a contributor. The iSRLs require intramuscular or deep subcutaneous injection with a wide bore needle that can be complicated by injection site pain, erythema, subcutaneous nodule formation, and for most individuals require attendance with a healthcare professional every 28 days to safely administered the medication. Two oral SRL (oSRL) formulations, Oral Octreotide Capsules and Paltusotine have been developed with clinical studies showing them to have promise as a therapeutic alternative to iSRL.

Keywords: acromegaly; lanreotide; ligand; octreotide; oral; paltusotine; somatostatin.

PubMed Disclaimer

References

    1. O. M. Dekkers, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. P. Vandenbroucke, “Mortality in Acromegaly: A Metaanalysis,” Journal of Clinical Endocrinology and Metabolism 93, no. 1 (January 2008): 61–67.
    1. M. Fleseriu, F. Langlois, D. S. T. Lim, E. V. Varlamov, and S. Melmed, “Acromegaly: Pathogenesis, Diagnosis, and Management,” Lancet Diabetes and Endocrinology 10, no. 11 (November 2022): 804–826.
    1. I. M. Holdaway, M. J. Bolland, and G. D. Gamble, “A Meta‐Analysis of the Effect of Lowering Serum Levels of GH and IGF‐I on Mortality in Acromegaly,” European Journal of Endocrinology 159 (2008): 89–95.
    1. N. Kyriakakis, K. Seejore, A. Hanafy, and R. D. Murray, “Management of Persistent Acromegaly Following Primary Therapy: The Current Landscape in the UK,” Endocrinology, Diabetes and Metabolism 3 (2020): e00158.
    1. N. Kyriakakis, J. Lynch, S. G. Gilbey, S. M. Webb, and R. D. Murray, “Impaired Quality of Life in Patients With Treated Acromegaly Despite Long‐Term Biochemically Stable Disease: Results From a 5‐years Prospective Study,” Clinical Endocrinology 86 (2017): 806–815.

Publication types

MeSH terms

LinkOut - more resources